

Summary of risk management plan for Quetiapin Orion (quetiapine fumarate) Orion Corporation

Date: 19.6.2018, Version 1.1

This is a summary of the risk management plan (RMP) for Quetiapin Orion. The RMP details important risks of Quetiapin Orion, how these risks can be minimized, and how more information will be obtained about Quetiapin Orion's risks and uncertainties (missing information).

Quetiapin Orion's summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Quetiapin Orion should be used.

Important new concerns or changes to the current ones will be included in updates of Quetiapin Orion's RMP.

I. The medicine and what it is used for

Quetiapin Orion is authorised for treatment of schizophrenia and bipolar disorder (see SmPC for the full indication). It contains quetiapine fumarate as the active substance and it is given by mouth.

II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of Quetiapin Orion, together with measures to minimise such risks and the proposed studies for learning more about Quetiapin Orion's risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute routine risk minimisation measures.

In the case of Quetiapin Orion, these measures are supplemented with *additional risk minimization measures* mentioned under relevant important risks, below.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed so that immediate action can be taken as necessary. These measures constitute *routine pharmacovigilance activities*.

If important information that may affect the safe use of Quetiapin Orion is not yet available, it is listed under 'missing information' below.

II.A List of important risks and missing information

Important risks of Quetiapin Orion are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely taken. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Quetiapin Orion. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine);

List of important risks and missing information	
Important identified risks	<ul style="list-style-type: none"> • Extrapyrimal symptoms (EPS) • Somnolence • Weight gain • Lipid changes (increased cholesterol [including increased LDLs], increased triglycerides, and decreased HDLs) • Hyperglycaemia and diabetes mellitus • Metabolic risk factors
Important potential risks	<ul style="list-style-type: none"> • Cerebrovascular adverse events in elderly • Cerebrovascular adverse events in non-elderly patients • Torsade de pointes • Ischaemic heart disease • Potential for off-label use and misdosing • Abuse and misuse
Missing information	<ul style="list-style-type: none"> • Use in pregnant or breast feeding women • Use in patients on concomitant cardiovascular medications • Use in patients on concomitant valproic acid

II.B Summary of important risks

The safety information in the proposed Product Information is aligned to the reference medicinal product.

Important identified risk: Extrapyrimal symptoms (EPS)	
Risk minimisation measures	Routine risk minimisation measures: Information in SmPC sections 4.4, 4.5, 4.6, 4.8 and 5.1, and PL sections 2 and 4. Additional risk minimisation measures: Educational material for healthcare professionals

Important identified risk: Somnolence	
Risk minimisation measures	Routine risk minimisation measures: Information in SmPC sections 4.4, 4.5, 4.6, 4.8, 4.9 and 5.1, and PL sections 2, 3 and 4. Additional risk minimisation measures: Educational material for healthcare professionals

Important identified risk: Weight gain	
Risk minimisation measures	<p>Routine risk minimisation measures:</p> <p>Information in SmPC sections 4.4, 4.5, 4.8 and 5.1, and PL sections 2 and 4.</p> <p>Additional risk minimisation measures:</p> <p>Educational material for healthcare professionals</p>
Important identified risk: Lipid changes (increased cholesterol [including increased LDLs], increased triglycerides, and decreased HDLs)	
Risk minimisation measures	<p>Routine risk minimisation measures:</p> <p>Information in SmPC sections 4.4 and 4.8, and PL section 4.</p> <p>Additional risk minimisation measures:</p> <p>Educational material for healthcare professionals</p>
Important identified risk: Hyperglycaemia and diabetes mellitus	
Risk minimisation measures	<p>Routine risk minimisation measures:</p> <p>Information in SmPC sections 4.4 and 4.8, and PL sections 2 and 4.</p> <p>Additional risk minimisation measures:</p> <p>Educational material for healthcare professionals</p>
Important identified risk: Metabolic risk factors	
Risk minimisation measures	<p>Routine risk minimisation measures:</p> <p>Information in SmPC sections 4.4 and 4.8, and PL sections 2 and 4.</p> <p>Additional risk minimisation measures:</p> <p>Educational material for healthcare professionals</p>
Important potential risk: Potential for off-label use and misdosing	
Risk minimisation measures	<p>Routine risk minimisation measures:</p> <p>Information in SmPC sections 4.1 and 4.2, and PL sections 1 and 3.</p> <p>Additional risk minimisation measures:</p> <p>Educational material for healthcare professionals</p>

II.C Post-authorisation development plan

There are no studies required for Quetiapin Orion.